PEPG logo

PEPG
PepGen Inc

1,021
Mkt Cap
$442.74M
Volume
462,384.00
52W High
$7.80
52W Low
$0.8801
PE Ratio
-2.27
PEPG Fundamentals
Price
$6.44
Prev Close
$6.79
Open
$6.73
50D MA
$5.65
Beta
1.30
Avg. Volume
734,315.95
EPS (Annual)
-$2.85
P/B
2.71
Rev/Employee
$0.00
$18.17
Loading...
Loading...
News
all
press releases
PepGen (PEPG) Expected to Announce Earnings on Monday
PepGen (NASDAQ:PEPG) will be releasing its Q4 2025 earnings before the market opens on Monday, February 23. (View Earnings Report at...
MarketBeat·16h ago
News Placeholder
More News
News Placeholder
PepGen (NASDAQ:PEPG) Trading Down 2.6% - What's Next?
PepGen (NASDAQ:PEPG) Stock Price Down 2.6% - Time to Sell...
MarketBeat·21d ago
News Placeholder
PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of "Moderate Buy" by Brokerages
PepGen, Inc. (NASDAQ:PEPG - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock, Marketbeat Ratings...
MarketBeat·1mo ago
News Placeholder
PepGen (NASDAQ:PEPG) Reaches New 12-Month High - What's Next?
PepGen (NASDAQ:PEPG) Sets New 12-Month High - Time to Buy...
MarketBeat·2mo ago
News Placeholder
PepGen Sees Unusually High Options Volume (NASDAQ:PEPG)
PepGen, Inc. (NASDAQ:PEPG - Get Free Report) was the target of unusually large options trading on Friday. Traders bought 8,010 call options on the company. This represents an increase of 649...
MarketBeat·2mo ago
News Placeholder
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%
The mean of analysts' price targets for PepGen (PEPG) points to a 75.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·2mo ago
News Placeholder
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and...
Business Wire·2mo ago
News Placeholder
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Hold" by Analysts
PepGen, Inc. (NASDAQ:PEPG - Get Free Report) has received a consensus rating of "Hold" from the six analysts that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the...
MarketBeat·2mo ago
News Placeholder
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and...
Business Wire·2mo ago
News Placeholder
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
Zacks·3mo ago
<
1
2
...
>

Latest PEPG News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.